MX2022008665A - Nuevo derivado de pirazol. - Google Patents

Nuevo derivado de pirazol.

Info

Publication number
MX2022008665A
MX2022008665A MX2022008665A MX2022008665A MX2022008665A MX 2022008665 A MX2022008665 A MX 2022008665A MX 2022008665 A MX2022008665 A MX 2022008665A MX 2022008665 A MX2022008665 A MX 2022008665A MX 2022008665 A MX2022008665 A MX 2022008665A
Authority
MX
Mexico
Prior art keywords
pyrazole derivative
novel pyrazole
novel
salt
pharmaceutical composition
Prior art date
Application number
MX2022008665A
Other languages
English (en)
Inventor
Sung Hwan Moon
Soo Jin Lee
Sung Chan Lee
Soo Ho Ban
Eun Sil Lee
Eun Jung Shin
Yoo-Kyung Goh
Hyun Kyung Yu
Original Assignee
Aptabio Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptabio Therapeutics Inc filed Critical Aptabio Therapeutics Inc
Publication of MX2022008665A publication Critical patent/MX2022008665A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La presente invención proporciona un compuesto derivado de pirazol novedoso representado por la fórmula química I o una sal del mismo, y una composición farmacéutica que comprende el mismo.
MX2022008665A 2020-01-13 2021-01-12 Nuevo derivado de pirazol. MX2022008665A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200004471 2020-01-13
PCT/KR2021/000425 WO2021145655A1 (ko) 2020-01-13 2021-01-12 신규한 피라졸 유도체

Publications (1)

Publication Number Publication Date
MX2022008665A true MX2022008665A (es) 2022-08-10

Family

ID=76864348

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008665A MX2022008665A (es) 2020-01-13 2021-01-12 Nuevo derivado de pirazol.

Country Status (13)

Country Link
US (1) US20230067461A1 (es)
EP (1) EP4105206A1 (es)
JP (1) JP2023511302A (es)
KR (1) KR102333863B1 (es)
CN (1) CN114945561A (es)
AU (1) AU2021208915B2 (es)
BR (1) BR112022013849A2 (es)
CA (1) CA3167675A1 (es)
CL (1) CL2022001888A1 (es)
CO (1) CO2022010431A2 (es)
IL (1) IL294674A (es)
MX (1) MX2022008665A (es)
WO (1) WO2021145655A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115916766A (zh) * 2021-02-25 2023-04-04 阿普塔生物治疗公司 新型吡唑衍生物
WO2023191201A1 (ko) * 2022-03-31 2023-10-05 압타바이오 주식회사 신규한 피라졸 유도체

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK574976A (da) * 1976-01-16 1977-07-17 Du Pont Substituerede cycloalkanpyrazoler samt deres fremstilling og anvendelse
AR045037A1 (es) * 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
EP2151433A1 (en) * 2008-08-05 2010-02-10 Institut Pasteur Alkoxypyrazoles and the process for their preparation
FR2953839A1 (fr) * 2009-12-14 2011-06-17 Sanofi Aventis Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
EP2361911A1 (en) * 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
TWI644671B (zh) * 2013-03-14 2018-12-21 比利時商健生藥品公司 Ｐ２ｘ７調節劑
CN106132967B (zh) 2014-03-27 2019-05-28 詹森药业有限公司 作为ros1抑制剂的化合物
US9708334B2 (en) * 2014-04-24 2017-07-18 Dart Neuroscience (Cayman) Ltd. Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine compounds as GlyT1 inhibitors
ES2824450T3 (es) 2015-06-22 2021-05-12 Actelion Pharmaceuticals Ltd Compuestos de benzoxazol y de benzotiazol 2,5-disustituidos como inhibidores de la NADPH oxidasa 4
JP6508721B2 (ja) 2015-09-28 2019-05-08 株式会社Ｓｃｒｅｅｎホールディングス 基板処理方法および基板処理装置
WO2019141957A1 (en) * 2018-01-19 2019-07-25 Cado Biotechnology Ivs N-pyrimidinyl hydroxy pyrazole derivatives and uses thereof

Also Published As

Publication number Publication date
CL2022001888A1 (es) 2023-02-24
CA3167675A1 (en) 2021-07-22
IL294674A (en) 2022-09-01
KR20210091063A (ko) 2021-07-21
WO2021145655A1 (ko) 2021-07-22
CN114945561A (zh) 2022-08-26
BR112022013849A2 (pt) 2022-09-13
AU2021208915A1 (en) 2022-09-01
CO2022010431A2 (es) 2022-08-09
JP2023511302A (ja) 2023-03-17
KR102333863B1 (ko) 2021-12-03
US20230067461A1 (en) 2023-03-02
AU2021208915B2 (en) 2024-02-22
EP4105206A1 (en) 2022-12-21

Similar Documents

Publication Publication Date Title
PH12020500673A1 (en) Compounds
MX2019010261A (es) Derivados de oxadiazol microbicidas.
MX2019003807A (es) Derivados de oxadiazol microbiocidas.
SG11201804121RA (en) Novel biphenyl compound or salt thereof
MX2018015854A (es) Derivados de oxadiazol microbiocidas.
MX2021005714A (es) Nuevos compuestos heterociclicos.
MX2019014104A (es) Compuesto novedoso de bifenilo o sal del mismo.
MX2018008412A (es) Derivados de oxadiazol microbicidas.
MY194676A (en) Sulfonamide compound or salt thereof
MX2022014864A (es) Compuestos de bisamida que activan el sarcomero y sus usos.
UA94833C2 (en) Substituted bicyclolactams
MY196809A (en) (),()-unsaturated amide compound
AU2019386994B2 (en) Microbiocidal 2-acylamino-thiazole-4-carboxamide derivatives
MY194116A (en) Pharmaceutical compounds
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
MX2022016515A (es) Nuevo inhibidor de la secrecion de acido y uso del mismo.
MX2021014680A (es) Derivado de benzotriazol.
EA202090368A1 (ru) Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1)
PH12018501241A1 (en) Heterocycle-substituted bicyclic azole pesticides
MX2022008665A (es) Nuevo derivado de pirazol.
MX2018001517A (es) Derivados sustituidos de guanidina.
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
AU2019408336A8 (en) Phenylpyrrolidine compound and use thereof
MX2023000926A (es) Nuevo derivado de pirazol.
WO2018102256A8 (en) Pyrrolidinone compounds